Feb 12, 2021 / 05:30PM GMT
Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
All right. Hello. I'm Michael Schmidt, senior biotech analyst with Guggenheim Securities, and it's my great pleasure to welcome Amgen to this year's Virtual Guggenheim Oncology Day.
With us today, we have Gregory Friberg, who is the Vice President of Global Development at Amgen; as well as Arvind Sood, who most of you know, who's heading up Investor Relations at Amgen. Welcome, guys, and thanks so much for joining us this year.
Gregory Friberg - Amgen Inc. - Head of Oncology Global Development
Thanks, Michael.
Arvind Sood - Amgen Inc. - VP of IR
Thank you, Michael.
Questions and Answers:
Michael Werner Schmidt - Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MDI thought, in the interest of time, I will jump right into Q&A. Maybe a bigger picture question upfront. Oncology is obviously one of the biggest and fastest-growing